| Abstrakt: |
Objective: To evaluate the impact and outcomes of our outpatient regimen in high-risk patients infected with SARS-Cov-2. Patients and Methods: We present a large case series ot high-risk patients with documented SARS-CoV-2 infection treated in our outpatient clinic. Our objective is to evaluate the feasibility, safety, and outcomes up to 30 days from initial treatment. Eligible patients were those at high risk for death as identified per the FDA EUA for bamlanivimab, SARS-Cov-2 antigen positive, and not hypoxemic on initial evaluation. A total of 551 patients were treated between November 17,2020, and February 28,2021. Our regimen had two components: A phase one antiviral combination with bamlanivimab orcasirivimab/imdevimab coupled with ivermectin, and a phase two component with tofacitinib and apixaban, targeting CO VID-19 pneumonia when diagnosed by CT scan. Results: A total of 551 high-risk patients were treated. A total of 14 patients were admitted (2.5% admission rate); none required intensive care and no deaths are recorded (0% mortality). Sixty-nine patients received upfront antivirals, tofacitinib and apixaban treatment for initial nonhypoxemic COVID-19 pneumonia. Two were admitted. The remaining 482 received antiviral therapy. Of these, 40 returned within 10 days with developing pneumonia and required tofacitinib and apixaban. Three were ad mitted. Another 9 had to be admitted after antiviral therapy without exposure to tofacitinib and apixaba n. Al 1 p atients were discharged alive, average length of stay 5.7 days. No ICU admissions or deaths occurred. Conclusion: Early administration of SARS-Cov-2 antivirals in high- risk patients coupled with treatment of those that present or progress to COVID-19 pneumonia with tofacitinib was well tolerated and associated w ith low hospitalization and no mortality. [ABSTRACT FROM AUTHOR] |
